Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing FDA warnings, patent cliffs, or controlled-substance quotas in ANI Pharmaceuticals’ disclosures can feel like decoding another language. Each annual report blends clinical trial data, DEA quota details, and manufacturing risk factors that easily surpass 200 pages. If you have ever searched for “ANI Pharmaceuticals insider trading Form 4 transactions” or tried to locate one footnote on steroid revenue, you know the challenge.
Stock Titan turns those challenges into clarity. Our platform delivers AI-powered summaries the moment an ANI Pharmaceuticals quarterly earnings report 10-Q filing or 8-K hits EDGAR, highlighting revenue by therapeutic class, fresh FDA correspondence, and supply-chain updates. Need real-time alerts? We surface ANI Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive buys and sells minutes after they post. From the ANI Pharmaceuticals annual report 10-K simplified to every ANI Pharmaceuticals 8-K material events explained, you receive concise language, key metrics, and cross-linked definitions—no accounting degree required.
Below you will find every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—each paired with an AI snapshot that answers the questions investors actually ask: cash flows by product line, R&D spend on rare-disease assets, or how “ANI Pharmaceuticals proxy statement executive compensation” aligns with pipeline milestones. Use our tools to:
- Run an “ANI Pharmaceuticals earnings report filing analysis” in seconds
- Track “ANI Pharmaceuticals executive stock transactions Form 4” before market open
- Master “understanding ANI Pharmaceuticals SEC documents with AI” without sifting through PDFs
Whether you are hunting for segment profitability or compliance triggers, Stock Titan delivers ANI Pharmaceuticals SEC filings explained simply—so you focus on decisions, not document digging.
Thomas Haughey, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 19,341 shares of the company's common stock on 08/12/2025 at a weighted-average price of $85.93 per share, according to this Form 4 filing. After the sale, Haughey beneficially owned 36,521 shares. The filing indicates the shares were sold in multiple trades at prices ranging from $84.50 to $87.16, and the form was signed by attorney-in-fact Meredith W. Cook on 08/14/2025.
The report is a standard Section 16 disclosure showing an insider disposition; it provides the exact quantities, price range, and resulting beneficial ownership recorded on the form.
ANI Pharmaceuticals (ANIP) notice reports a proposed sale of 47,010 shares of common stock via Merrill Lynch on 08/14/2025 with an aggregate market value of $4,206,603.82. The shares represent part of the outstanding share count of 21,688,772. The filer states the shares were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals and that the payment is a compensatory payment. No sales by the filer are reported in the prior three months. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
ANI Pharmaceuticals, Inc. (ANIP) filed a Form 144 notifying a proposed sale of 56,960 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $4,894,823.42. The form lists the approximate date of sale as 08/12/2025 and reports 21,688,772 shares outstanding for the issuer.
The securities to be sold were acquired as restricted stock from the issuer on four dates in 2025: 02/14 (12,333 shares), 02/28 (11,666), 03/07 (16,292), and 03/23 (16,669), which total the 56,960 shares listed for sale. The filing also states "Nothing to Report" for securities sold during the past three months and includes the standard signer representation that they do not possess undisclosed material adverse information. Certain filer identification and contact fields in the filing appear blank in the provided content.
ANI Pharmaceuticals (ANIP) has a Form 144 notice showing an insider proposes to sell 19,341 common shares, representing the full amount of two restricted stock grants received on 03/23/2022 (9,292 shares) and 04/27/2023 (10,049 shares). The planned sale is listed with an aggregate market value of $1,662,047.56 and an approximate sale date of 08/12/2025 on NASDAQ.
The shares to be sold compare with 21,699,636 shares outstanding, or roughly 0.09% of outstanding stock, and the filer reports no securities sold in the past three months. The filer also certifies they do not possess undisclosed material adverse information about the issuer.
ANI Pharmaceuticals (ANIP) filed a Form 144 notifying a proposed Rule 144 sale of 50,000 common shares to be handled by Morgan Stanley Smith Barney LLC on 08/12/2025 on the NASDAQ. The filing lists an aggregate market value of $4,303,590.00 and 21,699,636 shares outstanding, making the proposed sale roughly 0.23% of outstanding shares and implying an approximate price of $86.07 per share. The shares were reported as acquired the same day by stock option exercise from the issuer with cash payment. The filing reports no securities sold in the past three months. The extract does not include the filer identity or a dated signature in the provided content.
ANIP Q2-25 revenue jumped 53% YoY to $211.4 m, propelled by Cortrophin Gel (+66% to $81.6 m) and the first full quarter of ILUVIEN/YUTIQ sales ($22.3 m) acquired with Alimera. Generics grew 22% to $90.3 m.
Gross margin widened to 64.7% (58.2% LY) while SG&A climbed 55% on integration and commercial scale-up. Operating income rose to $13.9 m (6.6% margin) from $5.2 m; net income swung to $8.5 m, delivering diluted EPS of $0.36 versus a $0.14 loss. Six-month revenue is $408.5 m (+48%) with EPS of $1.05.
Cash reached $217.8 m as operating cash flow tripled to $110.8 m. Total debt remains high at $621.6 m (incl. $306.9 m converts), leaving net debt of ≈$404 m and leverage near 2.9× LTM sales. Intangible assets of $520 m and goodwill of $60.5 m reflect the Alimera deal; contingent consideration stands at $18.6 m.
Management stresses ongoing rare-disease momentum, manufacturing synergies and expanded market reach, but notes risks around debt covenants, rising rebate liabilities and Alimera integration.
FAQ
What is the current stock price of Ani Pharmaceutic (ANIP)?
What is the market cap of Ani Pharmaceutic (ANIP)?
